Europe Hereditary Genetic Testing Market – A Regional Analysis: Focus on Products, Sample Type, Applications, and Nordic and Baltic Region, Country Data (12 Countries), and Competitive Landscape – Analysis and Forecast, 2020-2031

$5,250$8,100

The market for Europe hereditary genetic testing is predicted to grow at a CAGR of 13.34% during the forecast period 2021-2031.

Clear
SKU: BHP1144SA Category: Tag:

Description

Market Report Coverage – Europe Hereditary Genetic Testing

Market Segmentation

• Product – Kits, Consumables, Services, Others
• Sample Type – Tumor Tissue, Bone Marrow, Blood, Saliva, Others
• Application – Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, Prenatal Screening and Preimplantation Testing, Rare Disease Testing, Direct-to-Consumer (DTC) Testing

Regional Segmentation

• EU5: Germany, U.K., France, Italy, Spain
• Nordic Region: Finland, Sweden, Denmark, Norway
• Baltic Region: Estonia, Lithuania, Latvia

Market Growth Drivers

• Increasing Awareness Toward Hereditary Genetic Testing
• Rising Prevalence of Genetic Disorders
• Increasing Research Funding in the Field of Genomics

Market Challenges

• High Cost of Genetic Testing
• Stringent Regulatory Standards

Market Opportunities

• Technological Advancements in the Hereditary Genetic Testing Process
• Growing Demand for Direct-to-Consumer (DTC) Testing Service

Key Companies Profiled

Agilent Technologies, Inc., Woble Helsinki Oy, Negen Oy, Devyser, CeGat GmbH, Beijing Genomics Institute (BGI), BerGenBio ASA, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Illumina, Inc., Myriad Genetics, Inc., Alnylam Pharmaceuticals, Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

• What is the current trend in the Europe hereditary genetic testing market?
• Based on products, which segment is anticipated to witness a massive rise in demand during the forecast period 2021-2031?
• Based on sample type, which segment is anticipated to witness a massive rise in demand during the forecast period 2021-2031?
• Based on types of testing, which segment is anticipated to witness a massive rise in demand during the forecast period 2021-2031?
• Based on countries, which country is anticipated to witness a massive rise in demand during the forecast period 2021-2031?
• What are the major drivers, challenges, and opportunities in the Europe hereditary genetic testing market?
• What are the key developmental strategies implemented by the key players to stand out in this market?
• Which leading companies are dominating the Europe hereditary genetic testing market, and what is the share of these companies in the Europe hereditary genetic testing market?
• What are the regulations pertaining to the Europe hereditary genetic testing market, and what initiatives have been implemented by different government bodies regulating the development and commercialization of Europe hereditary genetic testing?
• How is each segment of the Europe hereditary genetic testing market expected to grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2031?
• How is the market for Europe hereditary genetic testing expected to evolve during the forecast period 2021-2031?
• What is the market scenario for the Europe hereditary genetic testing market in different countries?
• What are the key trends of different regions in the Europe hereditary genetic testing market? Which country is expected to contribute to the highest sales in the Europe hereditary genetic testing market during the forecast period 2021-2031?

Europe Hereditary Genetic Testing Market Overview

Genetic testing is a type of DNA testing used to determine changes in chromosome structure or DNA sequence. Genetic testing can also include measuring the outcomes of genetic modifications, such as mutation, RNA analysis as an output of gene expression, or biochemical analysis to measure specific protein output. For cancer risk, genetic testing includes testing for inherited genetic variants that can be associated with a high to moderately increased risk of cancer in the patient and are responsible for inherited cancer susceptibility syndromes.

Hereditary genetic testing classifies changes in chromosomes, genes, and proteins. The outcome of hereditary genetic testing authorizes a suspected genetic condition that further helps to determine a person’s chance of passing or developing a genetic disorder. To date, more than 1,000 hereditary genetic tests have been used, and many others are being developed for testing.

Europe is one of the powerhouses for genomic science and research. Genetic testing data sharing is becoming an integral part as scientists join forces across borders for enabling genetic testing for the benefit of mankind. Genetic testing can be performed for various purposes, which may or may not fall in medical science. Thus, regulatory needs depend on the context of the test being performed and for which purpose. It can be either to detect monogenic diseases, medical-nonmedical purposes, predispositions or carrier tests, diagnostic and treatment purposes, predictive tests for late-onset diseases, drug response, family planning, forensics, population screening, and DNA profiling or research.

With several companies eagerly competing to establish dominance in the Europe hereditary genetic testing market, several emerging companies have undertaken significant activities to establish their position in the market. Although these companies are currently far behind the market leaders, some of them have made significant strides to grow into major players, owing to initiatives undertaken to expand their respective product portfolios and regional footprints.

Our healthcare experts have found hereditary genetic testing to be one of the most rapidly evolving markets. The market for Europe hereditary genetic testing is predicted to grow at a CAGR of 13.34% during the forecast period 2021-2031. As per CRI research, hereditary genetic testing comprises the ecosystem of multiple services offered, products used, and the target population.

The optimistic scenario of the market can be witnessed if the COVID-19 recovery is swift across key countries in Europe. The scenario assumes an increasing demand for technology, products, services, and growth in the end-user base across regions. Furthermore, the scenario also assumes more product and service launches for genetic testing, especially in the Nordic and Baltic regions. Additionally, the companies in the market are investing more in rare disease and reproductive genetics, which is one of the bolstering factors for optimistic growth.

The following report presents the reader with an opportunity to unlock comprehensive insights with respect to the Europe hereditary genetic testing market and helps in forming well-informed strategic decisions. The market research study also offers a wide perspective of the different types of hereditary genetic testing products and services available in the market and their impact on the diagnostic and genomics industry by providing critical insights into the direction of its future expansion.

The Europe hereditary genetic testing market has been growing since its inception. Several European countries, including Germany, France, the U.K., Italy, Spain, Denmark, Finland, Sweden, Norway, Estonia, Lithuania, and Latvia, are working persistently to enhance the adoption of precision medicine solutions, including hereditary genetic testing market, across Europe region. Acknowledging the unique role of hereditary genetic testing is a significant step toward the establishment of a suitable and effective regulatory approval procedure, coupled with an effective pricing strategy and reimbursement policy. However, country-specific technology evaluation and reimbursement policies in Europe may result in different coverage for many genetic testing technologies across Europe. For instance, in France, Germany, Italy, and the U.K., HER2 testing is publicly funded. However, in Spain, the majority of NGS testing is funded by hereditary-based test manufactures. Therefore, companies are trying to work closely with the payers and other decision-makers to increase the adoption on a country-by-country, and in few cases, hospital-by-hospital basis, which generally limits accessibility and results in a poor adoption rate.

Germany accounted for the maximum share of the market within the Europe region in 2020. The country has one of the biggest pharmaceutical markets in Europe. Further, it is among the largest exporter of medicinal products and ranks among the top pharmaceutical producers globally. The growth in this region can be primarily attributed to the rising pharmaceutical R&D expenditure, increasing geriatric population coupled with growing disease prevalence, and the rising focus to eradicate rare diseases across the region. However, the region also faces high competition from the Asian economies that offer cheap manufacturing materials and low cost of labor.

Within the research report, the market is segmented based on products, sample type, applications, and region. Each of these segments has been further categorized into sub-segments to compile an in-depth study. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The Europe hereditary genetic testing market is largely dominated by companies such as Woble Helsinki Oy, Negen Oy, Devyser, CeGaT GmbH, Beijing Genomics Institute (BGI), BerGenBio ASA, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Illumina, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Alnylam Pharmaceuticals, Inc., Quest Diagnostics Incorporated, and Thermo Fisher Scientific Inc.

Companies such as LabCorp, Illumina, Myriad, and Quest Diagnostics are the leading suppliers of genetic testing products and services in the Europe market. When compared to the other European countries, the Nordic and Baltic region is mainly dominated by Bluprint Genetics (Quest Diagnostics) and Eurofins. In addition, regional players such as Devyser, CeGat GmbH, and Negen Oy offer products in the markets.

Among the Nordic and Baltic regions, the Nordic region contributes more to the Europe hereditary genetic testing market. The country which performs the largest number of genetic tests in the Nordic region is Finland. A lot of investment in research for characterization of the population for rare diseases has been made in Finland by Blueprint Genetics.

Global Direct-to-Consumer Genetic Testing Market: Focus on Direct-to-Consumer Genetic Testing Market by Product Type, Distribution Channel, 15 Countries Mapping, and Competitive Landscape – Analysis and Forecast, 2021-2031

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Base Year

2021

Base Market Size

$5.52 Billion in 2021

Currency/Unit

USD

Forecast Year

2031

Market Size Forecast

$19.31 Billion by 2031

CAGR

13.34%

Table of Contents

1 Market Overview
1.1 Market Definition
1.2 Inclusions and Exclusions
1.3 Current State of Hereditary Genetic Testing in Europe
1.4 Market Footprint and Future Potential
1.5 Realistic and Optimistic View of Europe Hereditary Genetic Testing Market
2 Industry Analysis
2.1 Regulatory Framework in Europe
2.1.1 Overview
2.1.2 Legal Requirements
2.1.3 Workflow
2.1.4 Reimbursement Scenario
3 Market Dynamics
3.1 Market Dynamics
3.1.1 Drivers
3.1.1.1 Increasing Awareness Toward Hereditary Genetic Testing
3.1.1.2 Rising Prevalence of Genetic Disorders
3.1.1.3 Increasing Research Funding in the Field of Genomics
3.1.2 Restraints
3.1.2.1 High Cost of Genetic Testing
3.1.2.2 Stringent Regulatory Standards
3.1.3 Opportunities
3.1.3.1 Technological Advancements in the Hereditary Genetic Testing Process
3.1.3.2 Growing Demand for Direct-to-Consumer (DTC) Testing Service
4 Competitive Landscape
4.1 Overview
4.2 Synergistic Activities
4.2.1 Mergers and Acquisitions (M&A)
4.2.2 New Product Launches
4.2.3 Product Approvals
4.2.4 Business Expansions
4.3 Market Share Analysis, By Company
4.4 Growth Share Analysis, By Company
4.4.1 Inference
4.4.2 Inference
5 Product
5.1 Overview
5.1.1 Kits
5.1.2 Consumables
5.1.3 Services
5.1.4 Others
6 Sample Type
6.1 Overview
6.1.1 Tumor Tissue
6.1.2 Bone Marrow
6.1.3 Blood
6.1.4 Saliva
6.1.5 Others
7 Applications
7.1 Overview
7.1.1 Oncology Genetic Testing
7.1.1.1 Overview
7.1.1.2 Breast Cancer
7.1.1.3 Lung Cancer
7.1.1.4 Prostate Cancer
7.1.1.5 Colorectal Cancer
7.1.1.6 Melanoma
7.1.1.7 Other Oncology Genetic Testing Type
7.1.2 Cardiology Genetic Testing Type
7.1.2.1 Overview
7.1.2.2 Cardiomyopathy
7.1.2.3 Aortopathy
7.1.2.4 Arrhythmia
7.1.2.5 Other Cardiology Genetic Testing Type
7.1.3 Neurology Genetic Testing Type
7.1.3.1 Epilepsy
7.1.3.2 Neurodegenerative Disorders
7.1.3.3 Neuromuscular Disorders
7.1.3.4 Other Neurology Testing Type
7.1.4 Newborn Screening
7.1.5 Prenatal Screening and Preimplantation Testing
7.1.6 Rare Disease Testing
7.1.7 Direct-to-Consumer (DTC) Testing
8 Regions
8.1 Europe
8.1.1 Overview
8.2 EU5
8.2.1 Germany
8.2.2 U.K.
8.2.3 France
8.2.4 Italy
8.2.5 Spain
8.3 Nordic Region
8.3.1 Finland
8.3.1.1 Finland Hereditary Genetic Testing Market (by Product)
8.3.1.2 Finland Hereditary Genetic Testing Market (by Sample Type)
8.3.1.3 Finland Hereditary Genetic Testing Market (by Application)
8.3.1.4 Finland Hereditary Genetic Testing Market (by Oncology Genetic Testing Application)
8.3.1.5 Finland Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application)
8.3.1.6 Finland Hereditary Genetic Testing Market (by Neurology Genetic Testing Application)
8.3.2 Sweden
8.3.2.1 Sweden Hereditary Genetic Testing Market (by Product)
8.3.2.2 Sweden Hereditary Genetic Testing Market (by Sample Type)
8.3.2.3 Sweden Hereditary Genetic Testing Market (by Application)
8.3.2.4 Sweden Hereditary Genetic Testing Market (by Oncology Genetic Testing Application)
8.3.2.5 Sweden Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application)
8.3.2.6 Sweden Hereditary Genetic Testing Market (by Neurology Genetic Testing Application)
8.3.3 Denmark
8.3.3.1 Denmark Hereditary Genetic Testing Market (by Product)
8.3.3.2 Denmark Hereditary Genetic Testing Market (by Sample Type)
8.3.3.3 Denmark Hereditary Genetic Testing Market (by Application)
8.3.3.4 Denmark Hereditary Genetic Testing Market (by Oncology Genetic Testing Application)
8.3.3.5 Denmark Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application)
8.3.3.6 Denmark Hereditary Genetic Testing Market (by Neurology Genetic Testing Application)
8.3.4 Norway
8.3.4.1 Norway Hereditary Genetic Testing Market (by Product)
8.3.4.2 Norway Hereditary Genetic Testing Market (by Sample Type)
8.3.4.3 Norway Hereditary Genetic Testing Market (by Application)
8.3.4.4 Norway Hereditary Genetic Testing Market (by Oncology Genetic Testing Application)
8.3.4.5 Norway Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application)
8.3.4.6 Norway Hereditary Genetic Testing Market (by Neurology Genetic Testing Application)
8.4 Baltic Region
8.4.1 Estonia
8.4.1.1 Estonia Hereditary Genetic Testing Market (by Product)
8.4.1.2 Estonia Hereditary Genetic Testing Market (by Sample Type)
8.4.1.3 Estonia Hereditary Genetic Testing Market (by Application)
8.4.1.4 Estonia Hereditary Genetic Testing Market (by Oncology Genetic Testing Application)
8.4.1.5 Estonia Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application)
8.4.1.6 Estonia Hereditary Genetic Testing Market (by Neurology Genetic Testing Application)
8.4.2 Lithuania
8.4.2.1 Lithuania Hereditary Genetic Testing Market (by Product)
8.4.2.2 Lithuania Hereditary Genetic Testing Market (by Sample Type)
8.4.2.3 Lithuania Hereditary Genetic Testing Market (by Application)
8.4.2.4 Lithuania Hereditary Genetic Testing Market (by Oncology Genetic Testing Application)
8.4.2.5 Lithuania Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application)
8.4.2.6 Lithuania Hereditary Genetic Testing Market (by Neurology Genetic Testing Application)
8.4.3 Latvia
8.4.3.1 Latvia Hereditary Genetic Testing Market (by Product)
8.4.3.2 Latvia Hereditary Genetic Testing Market (by Sample Type)
8.4.3.3 Latvia Hereditary Genetic Testing Market (by Application)
8.4.3.4 Latvia Hereditary Genetic Testing Market (by Oncology Genetic Testing Application)
8.4.3.5 Latvia Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application)
8.4.3.6 Latvia Hereditary Genetic Testing Market (by Neurology Genetic Testing Application)
8.4.4 Rest-of-Europe
9 Company Profiles
9.1 Overview
9.2 Agilent Technologies, Inc.
9.2.1 Company Overview
9.2.2 Role of Agilent Technologies, Inc. in the Europe Hereditary Genetic Testing Market
9.2.3 Financials
9.2.4 Key Insights About Financial Health of the Company
9.2.5 SWOT Analysis
9.3 Woble Helsinki Oy
9.3.1 Company Overview
9.3.2 Role of Woble Helsinki Oy in the Europe Hereditary Genetic Testing Market
9.3.3 SWOT Analysis
9.4 Negen Oy
9.4.1 Company Overview
9.4.2 Role of Negen Oy in the Europe Hereditary Genetic Testing Market
9.4.3 SWOT Analysis
9.5 Devyser
9.5.1 Company Overview
9.5.2 Role of Devyser in the Europe Hereditary Genetic Testing Market
9.5.3 SWOT Analysis
9.6 CeGat GmbH
9.6.1 Company Overview
9.6.2 Role of CeGaT GmbH in the Europe Hereditary Genetic Testing Market
9.6.3 SWOT Analysis
9.7 Beijing Genomics Institute (BGI)
9.7.1 Company Overview
9.7.2 Role of Beijing Genomics Institute (BGI) in the Europe Hereditary Genetic Testing Market
9.7.3 SWOT Analysis
9.8 BerGenBio ASA
9.8.1 Company Overview
9.8.2 Role of BerGenBio ASA in the Europe Hereditary Genetic Testing Market
9.8.3 Financials
9.8.4 SWOT Analysis
9.9 Eurofins Scientific SE
9.9.1 Company Overview
9.9.2 Role of Eurofins Scientific SE in the Europe Hereditary Genetic Testing Market
9.9.3 Financials
9.9.4 SWOT Analysis
9.1 F. Hoffmann-La Roche Ltd
9.10.1 Company Overview
9.10.2 Role of F. Hoffmann-La Roche Ltd in the Europe Hereditary Genetic Testing Market
9.10.3 Financials
9.10.4 Key Insights About Financial Health of the Company
9.10.5 SWOT Analysis
9.11 Illumina, Inc.
9.11.1 Company Overview
9.11.2 Role of Illumina, Inc. in the Europe Hereditary Genetic Testing Market
9.11.3 Financials
9.11.4 Key Insights About Financial Health of the Company
9.11.5 SWOT Analysis
9.12 Myriad Genetics, Inc.
9.12.1 Company Overview
9.12.2 Role of Myriad Genetics, Inc. in the Europe Hereditary Genetic Testing Market
9.12.3 Financials
9.12.4 Key Insights About Financial Health of the Company
9.12.5 SWOT Analysis
9.13 Alnylam Pharmaceuticals, Inc.
9.13.1 Company Overview
9.13.2 Role of Alnylam Pharmaceuticals, Inc., in Europe Hereditary Genetic Testing Market
9.13.3 Financials
9.13.4 Key Insights About Financial Health of the Company
9.13.5 SWOT Analysis
9.14 Quest Diagnostics Incorporated
9.14.1 Company Overview
9.14.2 Role of Quest Diagnostics Incorporated in the Europe Hereditary Genetic Testing Market
9.14.3 Financials
9.14.4 SWOT Analysis
9.15 Thermo Fisher Scientific Inc.
9.15.1 Company Overview
9.15.2 Role of Thermo Fisher Scientific Inc. in the Europe Hereditary Genetic Testing Market
9.15.3 Financials
9.15.4 Key Insights About Financial Health of the Company
9.15.5 SWOT Analysis
List of Figures
Figure 1: Europe Hereditary Genetic Testing Market, Realistic and Optimistic Scenario, $Million, 2020-2031
Figure 2: Europe Hereditary Genetic Testing Market Dynamics
Figure 3: Share of Key Market Strategies and Developments, January 2018-March 2021
Figure 4: Growth Share Matrix for Europe Hereditary Genetic Testing Market (by Company), 2019 and 2020
Figure 5: Growth Share Matrix for Nordic and Baltic Hereditary Genetic Testing Market (by Company), 2019 and 2020
Figure 6: Europe Hereditary Genetic Testing Market Research Methodology
Figure 7: Primary Research Methodology
Figure 8: Incremental Opportunity: Europe Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 9: Realistic and Optimistic View of Europe Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 10: Europe Hereditary Genetic Testing Market Dynamics
Figure 11: Share of Key Market Strategies and Developments, January 2018-March 2021
Figure 12: Share of Synergistic Activities (by Company), January 2018-March 2021
Figure 13: Mergers and Acquisitions (M&A) Activities, January 2018-March 2021
Figure 14: New Product Launches, January 2018-March 2021
Figure 15: Market Share Analysis for Europe Hereditary Genetic Testing Market, $Million, 2019 and 2020
Figure 16: Market Share Analysis for Nordic and Baltic Hereditary Genetic Testing Market, 2019 and 2020
Figure 17: Growth Share Matrix for Europe Hereditary Genetic Testing Market (by Company), 2019 and 2020
Figure 18: Growth Share Matrix for Nordic and Baltic Hereditary Genetic Testing Market (by Company), 2019 and 2020
Figure 19: Europe Hereditary Genetic Testing Market (by Product)
Figure 20: Share of Europe Hereditary Genetic Testing Market (by Product), $Million, 2020 and 2031
Figure 21: Share of Nordic and Baltic Hereditary Genetic Testing Market (by Product), $Million, 2020 and 2031
Figure 22: Europe Hereditary Genetic Testing Market (Kits), $Million, 2020-2031
Figure 23: Europe Hereditary Genetic Testing Market (Consumables), $Million, 2020-2031
Figure 24: Europe Hereditary Genetic Testing Market (Services), $Million, 2020-2031
Figure 25: Europe Hereditary Genetic Testing Market (Others), $Million, 2020-2031
Figure 26: Europe Hereditary Genetic Testing Market (by Sample Type)
Figure 27: Share of Europe Hereditary Genetic Testing Market (by Sample Type), $Million, 2020 and 2031
Figure 28: Share of Nordic and Baltic Hereditary Genetic Testing Market (by Sample Type), $Million, 2020 and 2031
Figure 29: Europe Hereditary Genetic Testing Market (Tumor Tissue), $Million, 2020-2031
Figure 30: Europe Hereditary Genetic Testing Market (Bone Marrow), $Million, 2020-2031
Figure 31: Europe Hereditary Genetic Testing Market (Blood Sample), $Million, 2020-2031
Figure 32: Europe Hereditary Genetic Testing Market (Saliva), $Million, 2020-2031
Figure 33: Europe Hereditary Genetic Testing Market (Others), $Million, 2020-2031
Figure 34: Europe Hereditary Genetic Testing Market (by Application)
Figure 35: Europe Hereditary Genetic Testing Market (by Application), $Million, 2020 and 2031
Figure 36: Nordic and Baltic Hereditary Genetic Testing Market (by Application), $Million, 2020 and 2031
Figure 37: Europe Hereditary Genetic Testing Market (Oncology Genetic Testing), $Million, 2020-2031
Figure 38: Europe Hereditary Genetic Testing Market (Breast Cancer), $Million, 2020-2031
Figure 39: Europe Hereditary Genetic Testing Market (Lung Cancer), $Million, 2020-2031
Figure 40: Europe Hereditary Genetic Testing Market (Prostate Cancer), $Million, 2020-2031
Figure 41: Europe Hereditary Genetic Testing Market (Colorectal Cancer), $Million, 2020-2031
Figure 42: Europe Hereditary Genetic Testing Market (Melanoma), $Million, 2020-2031
Figure 43: Europe Hereditary Genetic Testing Market (Other Oncology Genetic Testing), $Million, 2020-2031
Figure 44: Europe Hereditary Genetic Testing Market (Cardiology Genetic Testing Type), $Million, 2020-2031
Figure 45: Europe Hereditary Genetic Testing Market (Cardiomyopathy), $Million, 2020-2031
Figure 46: Europe Hereditary Genetic Testing Market (Aortopathy), $Million, 2020-2031
Figure 47: Europe Hereditary Genetic Testing Market (Arrhythmia), $Million, 2020-2031
Figure 48: Europe Hereditary Genetic Testing Market (Other Cardiology Genetic Testing Type), $Million, 2020-2031
Figure 49: Europe Hereditary Genetic Testing Market (Neurology Genetic Testing Type), $Million, 2020-2031
Figure 50: Europe Hereditary Genetic Testing Market (Epilepsy), $Million, 2020-2031
Figure 51: Europe Hereditary Genetic Testing Market (Neurodegenerative Disorders), $Million, 2020-2031
Figure 52: Europe Hereditary Genetic Testing Market (Neuromuscular Disorders), $Million, 2020-2031
Figure 53: Europe Hereditary Genetic Testing Market (Other Neurology Testing Type), $Million, 2020-2031
Figure 54: Europe Hereditary Genetic Testing Market (Newborn Screening), $Million, 2020-2031
Figure 55: Europe Hereditary Genetic Testing Market (Prenatal Screening and Preimplantation Testing), $Million, 2020-2031
Figure 56: Europe Hereditary Genetic Testing Market (Rare Disease Testing), $Million, 2020-2031
Figure 57: Europe Hereditary Genetic Testing Market (Direct-to-Consumer (DTC) Testing), $Million, 2020-2031
Figure 58: Europe Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 59: Nordic Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 60: Baltic Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 61: Share of Europe Hereditary Genetic Testing Market (by Country), $Million, 2020-2031
Figure 62: Europe: Market Dynamics
Figure 63: Germany Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 64: U.K. Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 65: France Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 66: Italy Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 67: Spain Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 68: Finland Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 69: Finland Hereditary Genetic Testing Market (by Product), $Million, 2020-2031
Figure 70: Finland Hereditary Genetic Testing Market (by Sample Type), $Million, 2020-2031
Figure 71: Finland Hereditary Genetic Testing Market (by Application), $Million, 2020-2031
Figure 72: Finland Hereditary Genetic Testing Market (by Oncology Genetic Testing Application), $Million, 2020-2031
Figure 73: Finland Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application), $Million, 2020-2031
Figure 74: Finland Hereditary Genetic Testing Market (by Neurology Genetic Testing Application), $Million, 2020-2031
Figure 75: Sweden Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 76: Sweden Hereditary Genetic Testing Market (by Product), $Million, 2020-2031
Figure 77: Sweden Hereditary Genetic Testing Market (by Sample Type), $Million, 2020-2031
Figure 78: Sweden Hereditary Genetic Testing Market (by Application), $Million, 2020-2031
Figure 79: Sweden Hereditary Genetic Testing Market (by Oncology Genetic Testing Application), $Million, 2020-2031
Figure 80: Sweden Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application), $Million, 2020-2031
Figure 81: Sweden Hereditary Genetic Testing Market (by Neurology Genetic Testing Application), $Million, 2020-2031
Figure 82: Denmark Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 83: Denmark Hereditary Genetic Testing Market (by Product), $Million, 2020-2031
Figure 84: Denmark Hereditary Genetic Testing Market (by Sample Type), $Million, 2020-2031
Figure 85: Denmark Hereditary Genetic Testing Market (by Application), $Million, 2020-2031
Figure 86: Denmark Hereditary Genetic Testing Market (by Oncology Genetic Testing Application), $Million, 2020-2031
Figure 87: Denmark Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application), $Million, 2020-2031
Figure 88: Denmark Hereditary Genetic Testing Market (by Neurology Genetic Testing Application), $Million, 2020-2031
Figure 89: Norway Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 90: Norway Hereditary Genetic Testing Market (by Product), $Million, 2020-2031
Figure 91: Norway Hereditary Genetic Testing Market (by Sample Type), $Million, 2020-2031
Figure 92: Norway Hereditary Genetic Testing Market (by Application), $Million, 2020-2031
Figure 93: Norway Hereditary Genetic Testing Market (by Oncology Genetic Testing Application), $Million, 2020-2031
Figure 94: Norway Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application), $Million, 2020-2031
Figure 95: Norway Hereditary Genetic Testing Market (by Neurology Genetic Testing Application), $Million, 2020-2031
Figure 96: Estonia Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 97: Estonia Hereditary Genetic Testing Market (by Product), $Million, 2020-2031
Figure 98: Estonia Hereditary Genetic Testing Market (by Sample Type), $Million, 2020-2031
Figure 99: Estonia Hereditary Genetic Testing Market (by Application), $Million, 2020-2031
Figure 100: Estonia Hereditary Genetic Testing Market (by Oncology Genetic Testing Application), $Million, 2020-2031
Figure 101: Estonia Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application), $Million, 2020-2031
Figure 102: Estonia Hereditary Genetic Testing Market (by Neurology Genetic Testing Application), $Million, 2020-2031
Figure 103: Lithuania Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 104: Lithuania Hereditary Genetic Testing Market (by Product), $Million, 2020-2031
Figure 105: Lithuania Hereditary Genetic Testing Market (by Sample Type), $Million, 2020-2031
Figure 106: Lithuania Hereditary Genetic Testing Market (by Application), $Million, 2020-2031
Figure 107: Lithuania Hereditary Genetic Testing Market (by Oncology Genetic Testing Application), $Million, 2020-2031
Figure 108: Lithuania Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application), $Million, 2020-2031
Figure 109: Lithuania Hereditary Genetic Testing Market (by Neurology Genetic Testing Application), $Million, 2020-2031
Figure 110: Latvia Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 111: Latvia Hereditary Genetic Testing Market (by Product), $Million, 2020-2031
Figure 112: Latvia Hereditary Genetic Testing Market (by Sample Type), $Million, 2020-2031
Figure 113: Latvia Hereditary Genetic Testing Market (by Application), $Million, 2020-2031
Figure 114: Latvia Hereditary Genetic Testing Market (by Oncology Genetic Testing Application), $Million, 2020-2031
Figure 115: Latvia Hereditary Genetic Testing Market (by Cardiology Genetic Testing Application), $Million, 2020-2031
Figure 116: Latvia Hereditary Genetic Testing Market (by Neurology Genetic Testing Application), $Million, 2020-2031
Figure 117: Rest-of-Europe Hereditary Genetic Testing Market, $Million, 2020-2031
Figure 118: Total Number of Companies Profiled
Figure 119: Agilent Technologies, Inc.: Product Portfolio
Figure 120: Agilent Technologies, Inc.: Overall Financials, 2018-2020
Figure 121: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
Figure 122: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 123: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
Figure 124: Agilent Technologies, Inc.: SWOT Analysis
Figure 125: Woble Helsinki Oy: Product Portfolio
Figure 126: Woble Helsinki Oy: SWOT Analysis
Figure 127: Negen Oy: Product Portfolio
Figure 128: Negen Oy: SWOT Analysis
Figure 129: Devyser: Product Portfolio
Figure 130: Devyser: SWOT Analysis
Figure 131: CeGaT GmbH: Product Portfolio
Figure 132: CeGaT GmbH: SWOT Analysis
Figure 133: BGI: Product Portfolio
Figure 134: BGI: SWOT Analysis
Figure 135: BerGenBio ASA: Overall Financials, 2018-2020
Figure 136: BerGenBio ASA: Overall Product Portfolio
Figure 137: BerGenBio ASA: SWOT Analysis
Figure 138: Eurofins Scientific SE: Overall Financials, 2018-2020
Figure 139: Eurofins Scientific SE: Revenue (by Region), 2018-2020
Figure 140: Eurofins Scientific SE.: SWOT Analysis
Figure 141: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 142: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
Figure 143: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2018-2020
Figure 144: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2018-2020
Figure 145: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020
Figure 146: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 147: Illumina, Inc.: Product Portfolio
Figure 148: Illumina, Inc.: Overall Financials, 2018-2020
Figure 149: Illumina, Inc.: Revenue (by Segment), 2018-2020
Figure 150: Illumina, Inc.: R&D Expenditure, 2018-2020
Figure 151: Illumina, Inc.: SWOT Analysis
Figure 152: Myriad Genetics, Inc.: Product Portfolio
Figure 153: Myriad Genetics, Inc.: Overall Financials, 2018-2020
Figure 154: Myriad Genetics, Inc.: Revenue (by Segment), 2018-2020
Figure 155: Myriad Genetics, Inc.: R&D Expenditure,2018-2020
Figure 156: Myriad Genetics, Inc.: SWOT Analysis
Figure 157: Alnylam Pharmaceuticals, Inc.: Overall Financials, 2018-2020
Figure 158: Alnylam Pharmaceuticals, Inc.: Revenue (by Segment), 2018-2020
Figure 159: Alnylam Pharmaceuticals, Inc.: Revenue (by Region), 2018-2020
Figure 160: Alnylam Pharmaceuticals, Inc.: R&D Expenditure, 2018-2020
Figure 161: Alnylam Pharmaceuticals, Inc.: SWOT Analysis
Figure 162: Product Portfolio: Quest Diagnostics Incorporated
Figure 163: Quest Diagnostics Incorporated: Overall Financials, 2018-2020
Figure 164: Quest Diagnostics Incorporated: Revenue (by Segment), 2018-2020
Figure 165: Quest Diagnostics Incorporated: SWOT Analysis
Figure 166: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 167: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
Figure 168: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2018-2020
Figure 169: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
Figure 170: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 171: Thermo Fisher Scientific Inc.: SWOT Analysis
List of Tables
Table 1: Legal and Regulatory Framework